Adicet Bio Inc (ACET) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Adicet Bio Inc stock (ACET) is currently trading at $6.69. Adicet Bio Inc PS ratio (Price-to-Sales) is 9.72. Analyst consensus price target for ACET is $56.83. WallStSmart rates ACET as Sell.
- ACET PE ratio analysis and historical PE chart
- ACET PS ratio (Price-to-Sales) history and trend
- ACET intrinsic value — DCF, Graham Number, EPV models
- ACET stock price prediction 2025 2026 2027 2028 2029 2030
- ACET fair value vs current price
- ACET insider transactions and insider buying
- Is ACET undervalued or overvalued?
- Adicet Bio Inc financial analysis — revenue, earnings, cash flow
- ACET Piotroski F-Score and Altman Z-Score
- ACET analyst price target and Smart Rating
Adicet Bio Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Adicet Bio Inc (ACET) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in peg ratio, price/book, institutional own.. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Adicet Bio Inc (ACET) Key Strengths (3)
Growing significantly faster than its price suggests
Trading below book value, meaning the market prices it less than net assets
69.69% held by institutions, strong professional interest
Supporting Valuation Data
Adicet Bio Inc (ACET) Areas to Watch (4)
Company is destroying shareholder value
Revenue declining -100.00%, a shrinking business
Very expensive at 9.7x annual revenue
Micro-cap company with very limited liquidity and high volatility
Supporting Valuation Data
Adicet Bio Inc (ACET) Detailed Analysis Report
Overall Assessment
This company scores 33/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 3 register as strengths (avg 9.3/10) while 4 fall into concern territory (avg 1.3/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on PEG Ratio, Price/Book, Institutional Own.. Valuation metrics including PEG Ratio (0.82), Price/Book (0.42) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Revenue Growth, Price/Sales. Some valuation metrics including Price/Sales (9.72) suggest expensive pricing. Growth concerns include Revenue Growth at -100.00%, which may limit upside. Profitability pressure is visible in Return on Equity at -67.50%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -67.50% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -100.00% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Revenue Growth are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
ACET Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
ACET's Price-to-Sales ratio of 9.72x sits near its historical average of 8.91x (68th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 92% below its historical high of 119.93x set in Nov 2020, and 6380% above its historical low of 0.15x in Dec 2018. Over the past 12 months, the PS ratio has expanded from ~0.3x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Adicet Bio Inc (ACET) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Adicet Bio Inc operates as a stable business with moderate growth and solid fundamentals. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Revenue contracted 100% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -21M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Volatility is elevated with a beta of 1.61, so expect amplified moves relative to the broader market.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Adicet Bio Inc.
Bottom Line
Adicet Bio Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Adicet Bio Inc(ACET)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company is headquartered in Boston, Massachusetts.